| Autor: |
Shammas NW; Genesis Heart Institute, Davenport, IA 52803, USA. shammas@mchsi.com, Kapalis MJ, Deckert J, Harris M, Dippel EJ, Labroo A, McKinney D |
| Jazyk: |
angličtina |
| Zdroj: |
Preventive cardiology [Prev Cardiol] 2003 Fall; Vol. 6 (4), pp. 189-94. |
| DOI: |
10.1111/j.1520-037x.2003.02200.x |
| Abstrakt: |
This retrospective study was carried out to assess the effectiveness of statin-gemfibrozil combination therapy in a community practice lipid clinic and to review safety data from published literature. Forty-six consecutive patients received a statin and gemfibrozil combination for resistant hyperlipidemia to either agent therapy. Fasting total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), and triglycerides (mg/dL) were measured. Low-density lipoprotein cholesterol (mg/dL) was calculated using the Friedewald formula if triglycerides were <400 mg/dL. Combination therapy reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides by 11% (p=0.02), 22% (p=0.049), and 39% (p=0.0002), respectively, and raised high-density lipoprotein cholesterol by 5% (p=0.3). A pooled analysis of 838 patients from the literature on statin-gemfibrozil combination therapy revealed an incidence of myositis and severe myopathy of 0.7% and 0.6%, respectively (excluding cerivastatin). We conclude that statin-gemfibrozil combination therapy is effective in significantly reducing total cholesterol, low-density lipoprotein cholesterol, and triglycerides with a trend toward raising high-density lipoprotein cholesterol in patients with hyperlipidemia resistant to either agent alone. Myositis and severe myopathy are infrequent, but not rare side effects which may be statin-specific regarding the incidence of occurrence. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text